Please use this identifier to cite or link to this item: https://repository.monashhealth.org/monashhealthjspui/handle/1/45460
Conference/Presentation Title: Long-term outcomes of probiotic and peanut oral immunotherapy (the PPOIT-002 study).
Authors: Loke P.;Hsiao K.;Lozinsky A.;Pitkin S.;Axelrad C.;Ashley S.;Lloyd M.;Tey D.;Robinson M.;Su E.;Orsini F.;Tang M.L.
Monash Health Department(s): Diabetes and Vascular Medicine
Institution: (Loke) Monash Children's Hospital, Clayton, Australia
(Loke, Hsiao, Lozinsky, Pitkin, Axelrad, Ashley, Lloyd, Tey, Su, Orsini, Tang) Murdoch Children's Research Institute, Parkville, Australia
(Loke, Ashley, Tey, Robinson, Su, Tang) Royal Children's Hospital, Parkville, Australia
(Loke, Tang) University of Melbourne, Melbourne, Australia
(Hsiao) Starship Children's Hospital, Auckland, New Zealand
(Hsiao) University of Auckland, Auckland, New Zealand
Presentation/Conference Date: 9-Dec-2021
Copyright year: 2021
Publisher: Blackwell Publishing Ltd
Publication information: Allergy: European Journal of Allergy and Clinical Immunology. Conference: European Academy of Allergy and Clinical Immunology Hybrid Congress, EAACI 2021. Krakow Poland. 76(SUPPL 110) (pp 541), 2021. Date of Publication: November 2021.
Journal: Allergy: European Journal of Allergy and Clinical Immunology
Abstract: Background: Probiotic and peanut oral immunotherapy (PPOIT) induced long-term sustained unresponsiveness (SU) in a proof-of- concept Phase 2a randomized trial. This open-label study (PPOIT-002) aimed to confirm the tolerability and long-term effects of PPOIT in children with peanut allergy aged 1-12 years. Method(s): 20 children aged 1-12 years with double-blind placebo-controlled food challenge (DBPCFC)-confirmed peanut allergy received 18 months of PPOIT. DBPCFC (cumulative 4950mg peanut protein) were performed at end-of- treatment, 8-weeks post-treatment and 3-years post-treatment to assess for desensitisation, SU and long-term SU, respectively. Immunologic measures, peanut skin prick test (SPT) and specific IgE (sIgE), were evaluated at screening, end-of- treatment and 3-years post-treatment. Continuous outcomes for peanut SPT and sIgE were compared between timepoints using paired t-tests and paired Wilcoxon signed rank test, respectively. Result(s): Sixteen children (75%) completed study treatment. Intention-to- treat analysis showed desensitisation and 8-week SU rates of 75% (15/20) and 60% (12/20), respectively. 10 of the 12 children who achieved 8-week SU at the end-of- treatment consented to the 3-year long-term 8-week SU challenge, with 6 (60%) maintaining long-term SU. PPOIT was associated with decreased peanut SPT and sIgE levels, with significant reductions persisting at 3-years post-treatment (p =0.0022 and p =0.0012, respectively). 17 of 20 (85%) of children reported treatment-related adverse events (AE) (total 176 events). The majority of AEs (164; 93%) were mild. There were no serious AEs. Conclusion(s): This open label study demonstrated that 18 months of PPOIT induced high rates of desensitisation and 8-week SU, with persistence of SU at 3-years post-treatment in the majority of initial responders. PPOIT led to long-lasting reduction in peanut sIgE, suggesting modulation of the underlying allergic response to peanut.
Conference Name: European Academy of Allergy and Clinical Immunology Hybrid Congress, EAACI 2021
Conference Start Date: 20210-7-10
Conference End Date: 20210-7-12
Conference Location: Krakow, Poland
DOI: http://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1111/all.15096
URI: https://repository.monashhealth.org/monashhealthjspui/handle/1/45460
Type: Conference Abstract
Subjects: allergic reaction
desensitization
gene expression
immunoglobulin blood level
infant
oral immunotherapy
peanut allergy
phase 2
prick test
protein expression
Wilcoxon signed ranks test
immunoglobulin E
probiotic agent
Appears in Collections:Conference Abstracts

Show full item record

Page view(s)

220
checked on Oct 11, 2025

Google ScholarTM

Check


Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.